Connect your AI

Medifast MED Thereafter

Other financials

Income statement

Revenue$76.0M-34.3%

Gross profit$51.8M-38.6%

Operating income-$3.3M-161%

Net income-$2.1M-175%

EPS (diluted)-$0.19-171%

Balance sheet

Cash & equivalents$71.5M-22.0%

Total debt$16.1M+10.2%

Total equity$197.7M-6.3%

Total assets$252.0M-10.0%

Cash flow

Operating cash flow$260.0K-92.4%

CapEx$1.1M-28.0%

Free cash flow-$836.0K-144%

Valuation

Market cap$121.87M-17.4%

Enterprise value$66.44M+12.8%

P/S0.4×0.0×

Profitability

Gross margin70.1%-3.8pp

Operating margin-4.7%-7.0pp

Net margin-5.8%-8.1pp

FCF margin5%-9.3pp

Returns & leverage

Return on equity-9.8%-20.1pp

Debt / equity0.1×0.0×

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Medifast in its filing.

Tagged under the XBRL concept med:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour.

The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medifast's thereafter.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Medifast's thereafter?: Medifast (MED) reported thereafter of $4.25M in Q1 2026.